Showing 1671-1680 of 1922 results for "".
- Takeda CEO Optimistic About Growth Prospects as Drugmaker Finalizes Shire Takeoverhttps://modernod.com/news/takeda-ceo-optimistic-about-growth-prospects-as-drugmaker-finalizes-shire-takeover/2476205/Takeda announced that it has completed its $62-billion acquisition of Shire. Christophe Weber, chief executive of Takeda, stated “this marks a significant moment in [our] history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicin
- California Optometrists Caution Patients About Unapproved, Online Vision Tests After FDA Warninghttps://modernod.com/news/california-optometrists-caution-patients-about-unapproved-online-vision-tests-after-fda-warning/2480161/The California Optometric Association cautioned California consumers that self-administered “vision tests” conducted online come with significant safety concerns and appear to violate federal law, according to a news release. In a letter to the California Attorney General, the organization
- FDA Recall Prompts Nationwide Warning Over Millions of Eye Dropshttps://modernod.com/news/fda-recall-prompts-nationwide-warning-over-millions-of-eye-drops/2486525/Key Takeaways More than 3.1 million bottles of store-brand eye drops have been recalled nationwide due to concerns about product sterility
- AAO: Office-Based Cataract Surgery Study Shows Success With Minimal Oral Sedationhttps://modernod.com/news/aao-office-based-cataract-surgery-study-shows-success-with-minimal-oral-sedation/2484197/A new study presented at the 129th annual meeting of the American Academy of Ophthalmology (AAO) is challenging long-held assumptions about cataract surgery. The research demonstrates that patients can safely and successfully undergo office-based cataract surgery u
- jCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RPhttps://modernod.com/news/jcyte-initiates-patient-dosing-in-phase-2-jc02-88-trial-of-jcell-for-rp/2484125/jCyte announced that the first patients have been enrolled and treated in the JC02-88 study, a phase 2 clinical trial evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The study is testing a jCell dose about 5
- EMA Review Finds Rare Risk of Vision Loss Associated With Semaglutide Medicineshttps://modernod.com/news/ema-review-finds-rare-risk-of-vision-loss-associated-with-semaglutide-medicines/2482842/The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines following concerns about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAIO
- Alcon Boosts Femtosecond Laser Portfolio with Acquisition of Lensarhttps://modernod.com/news/alcon-boosts-femtosecond-laser-technology-with-acquisition-of-lensar/2482713/Alcon and Lensar have entered into a definitive merger agreement through which Alcon intends to acquire Lensar for about $356 million. The acquisition includes ALLY Robotic Cataract Laser Treatment System, Lensar’s proprietary Streamline software technology, and Lensar
- Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DMEhttps://modernod.com/news/oculis-accelerates-enrollment-for-phase-3-diamond-trials-of-ocs-01-eye-drops-in-diabetic-macular-edema/2482504/Oculis announced significant progress in patient enrollment for both phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program, designed to assess the efficacy and safety of OCS-01, an investigational eye drop, has enrolled about 70% of patients in the phase
- Participants of Experimental CRISPR Gene Editing Trial See Vision Improvehttps://modernod.com/news/participants-of-experimental-crispr-gene-editing-trial-see-vision-improve/2482277/About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine, the National Eye Institut
- Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-dutch-ophthalmic-research-center/2482210/Carl Zeiss Meditec announced it has secured all required regulatory approvals and completed the acquisition of Dutch Ophthalmic Research Center (DORC). IN December, Zeiss announced its plans to acquire from the investment firm Eurazeo SE (Paris, France) for about €985 million ($1.0